<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Platelets become activated and accumulate in brain microvessels of the ischemic microvascular bed after experimental focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The binding of <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> IIb/IIIa (integrin alpha(IIb)beta(3)) on platelets to fibrinogen is the terminal step in platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and aggregation </plain></SENT>
<SENT sid="2" pm="."><plain>This study tests the hypothesis that inhibition of platelet-fibrin(ogen) interactions may prevent microvascular occlusion after experimental middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (<z:chebi fb="70" ids="34342">MCA</z:chebi>:O) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: TP9201 is a novel Arg-Gly-Asp (RGD)-containing integrin alpha(IIb)beta(3) inhibitor </plain></SENT>
<SENT sid="4" pm="."><plain>Microvascular patency after 3-hour <z:chebi fb="70" ids="34342">MCA</z:chebi>:O and 1-hour reperfusion within the ischemic and nonischemic basal ganglia was compared in adolescent male baboons who received high-dose TP9201 (group A: IC(80) in <z:chebi fb="5" ids="28304">heparin</z:chebi>, n=4), low-dose TP9201 (group B: IC(30) in <z:chebi fb="5" ids="28304">heparin</z:chebi>, n=4), or no treatment (group C: n=4) before <z:chebi fb="70" ids="34342">MCA</z:chebi>:O </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: After <z:chebi fb="70" ids="34342">MCA</z:chebi>:O, microvascular patency decreased significantly in group C </plain></SENT>
<SENT sid="6" pm="."><plain>However, in the ischemic zones of groups A and B compared with group C, patencies were significantly greater in the 4.0- to 7 </plain></SENT>
<SENT sid="7" pm="."><plain>5-microm-diameter (capillary) and 7.5- to 30.0-microm-diameter vessels (2P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>A dose-dependent increase in hemorrhagic transformation was seen in group A (3 of 4 animals) compared with group B (1 of 4 animals), and no <z:mp ids='MP_0001914'>hemorrhage</z:mp> was visible in group C (chi(2) analysis for trend, P&lt;0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Platelet activation contributes significantly to ischemic microvascular occlusion </plain></SENT>
<SENT sid="10" pm="."><plain>Occlusion formation may be prevented by this RGD-integrin alpha(IIb)beta(3) inhibitor at a dose that does not produce clinically significant parenchymal <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>The effect of microvascular patency on neuron recovery can now be tested </plain></SENT>
</text></document>